Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC)
ANNALS OF ONCOLOGY(2022)
Abstract
NIVO plus chemotherapy demonstrated superior overall survival (OS) versus chemotherapy in metastatic EGC (Janjigian et al, Lancet 2021). We report preliminary results of a single center investigator initiated phase II study of first-line REGO with NIVO and FOLFOX in this population.
MoreTranslated text
Key words
negative esophagogastric cancer,1227p regorafenib,nivolumab
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined